<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35575811</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1432-1459</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>16</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neurology</Title>
          <ISOAbbreviation>J Neurol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11165-0</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cognitive and behavioural symptoms due to involvement of the central nervous system (CNS) are among the main clinical manifestations of Myotonic Dystrophy type 1 (DM1). Such symptoms affect patients' quality of life and disease awareness, impacting on disease prognosis by reducing compliance to medical treatments. Therefore, CNS is a key therapeutic target in DM1. Deeper knowledge of DM1 pathogenesis is prompting development of potential disease-modifying therapies: as DM1 is a rare, multisystem and slowly progressive disease, there is need of sensitive, tissue-specific prognostic and monitoring biomarkers in view of forthcoming clinical trials. Circulating Neurofilament light chain (NfL) levels have been recognized as a sensitive prognostic and monitoring biomarker of neuroaxonal damage in various CNS disorders.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">We performed a cross-sectional study in a cohort of 40 adult DM1 patients, testing if serum NfL might be a potential biomarker of CNS involvement also in DM1. Moreover, we collected cognitive data, brain MRI, and other DM1-related diagnostic findings for correlation studies.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Mean serum NfL levels resulted significantly higher in DM1 (25.32 ± 28.12 pg/ml) vs 22 age-matched healthy controls (6.235 ± 0.4809 pg/ml). Their levels positively correlated with age, and with one cognitive test (Rey's Auditory Verbal learning task). No correlations were found either with other cognitive data, or diagnostic parameters in the DM1 cohort.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings support serum NfL as a potential biomarker of CNS damage in DM1, which deserves further evaluation on larger cross-sectional and longitudinal studies to test its ability in assessing brain disease severity and/or progression.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Nicoletti</LastName>
            <ForeName>Tommaso F</ForeName>
            <Initials>TF</Initials>
            <Identifier Source="ORCID">0000-0002-9335-1218</Identifier>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UOC Neurologia - Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Rossi</LastName>
            <ForeName>Salvatore</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UOC Neurologia - Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vita</LastName>
            <ForeName>Maria Gabriella</ForeName>
            <Initials>MG</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UOC Neurologia - Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Perna</LastName>
            <ForeName>Alessia</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UOC Neurologia - Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Guerrera</LastName>
            <ForeName>Gisella</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Unità di Neuroimmunologia, Fondazione Santa Lucia IRCCS, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lino</LastName>
            <ForeName>Federica</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UOC Neurologia - Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Iacovelli</LastName>
            <ForeName>Chiara</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>UOC Riabilitazione e Medicina Fisica-Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Di Natale</LastName>
            <ForeName>Daniele</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UOC Neurologia - Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Modoni</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UOC Neurologia - Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Battistini</LastName>
            <ForeName>Luca</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Unità di Neuroimmunologia, Fondazione Santa Lucia IRCCS, Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Silvestri</LastName>
            <ForeName>Gabriella</ForeName>
            <Initials>G</Initials>
            <Identifier Source="ORCID">0000-0002-1950-1468</Identifier>
            <AffiliationInfo>
              <Affiliation>Dipartimento di Neuroscienze, Università Cattolica del Sacro Cuore, Largo F. Vito 1, 00168, Rome, Italy. gabriella.silvestri@unicatt.it.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>UOC Neurologia - Dipartimento Scienze dell'Invecchiamento, Neurologiche, Ortopediche e della Testa-Collo, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo Agostino Gemelli, 8, 00168, Rome, Italy. gabriella.silvestri@unicatt.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>J Neurol</MedlineTA>
        <NlmUniqueID>0423161</NlmUniqueID>
        <ISSNLinking>0340-5354</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Biomarkers</Keyword>
        <Keyword MajorTopicYN="N">Central nervous system</Keyword>
        <Keyword MajorTopicYN="N">Cognition</Keyword>
        <Keyword MajorTopicYN="N">Myotonic dystrophy</Keyword>
        <Keyword MajorTopicYN="N">Neurofilament protein</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>16</Day>
          <Hour>13</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>17</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35575811</ArticleId>
        <ArticleId IdType="doi">10.1007/s00415-022-11165-0</ArticleId>
        <ArticleId IdType="pii">10.1007/s00415-022-11165-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Harper PS (2001) Myotonic Dystrophy, 3rd edn. Harcourt Publishers Ltd, London</Citation>
        </Reference>
        <Reference>
          <Citation>Ashizawa T, Sarkar PS (2011) Myotonic dystrophy types 1 and 2. Handb Clin Neurol 101:193–237. https://doi.org/10.1016/B978-0-08-045031-5.00015-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/B978-0-08-045031-5.00015-3</ArticleId>
            <ArticleId IdType="pubmed">21496635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lavedan C, Hofmann-Radvanyi H, Shelbourne P et al (1993) Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism. Am J Hum Genet 52(5):875–883</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8098180</ArticleId>
            <ArticleId IdType="pmc">1682032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Antonio M, Dogan C, Hamroun D et al (2016) Unravelling the myotonic dystrophy type 1 clinical spectrum: a systematic registry-based study with implications for disease classification. Rev Neurol (Paris) 172(10):572–580. https://doi.org/10.1016/j.neurol.2016.08.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.neurol.2016.08.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>López-Martínez A, Soblechero-Martín P, de-la-Puente-Ovejero L, Nogales-Gadea G, Arechavala-Gomeza V. An overview of alternative splicing defects implicated in myotonic dystrophy type I. Genes (Basel). 2020;11(9):1109. https://doi.org/10.3390/genes11091109</Citation>
        </Reference>
        <Reference>
          <Citation>Okkersen K, Buskes M, Groenewoud J et al (2017) The cognitive profile of myotonic dystrophy type 1: A systematic review and meta-analysis. Cortex 95:143–155. https://doi.org/10.1016/j.cortex.2017.08.008</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cortex.2017.08.008</ArticleId>
            <ArticleId IdType="pubmed">28892766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okkersen K, Monckton DG, Le N, Tuladhar AM, Raaphorst J, van Engelen BGM (2017) Brain imaging in myotonic dystrophy type 1: A systematic review. Neurology 89(9):960–969. https://doi.org/10.1212/WNL.0000000000004300</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000004300</ArticleId>
            <ArticleId IdType="pubmed">28768849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weber YG, Roebling R, Kassubek J et al (2010) Comparative analysis of brain structure, metabolism, and cognition in myotonic dystrophy 1 and 2. Neurology 74(14):1108–1117. https://doi.org/10.1212/WNL.0b013e3181d8c35f</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181d8c35f</ArticleId>
            <ArticleId IdType="pubmed">20220122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peric S, Brajkovic L, Belanovic B et al (2017) Brain positron emission tomography in patients with myotonic dystrophy type 1 and type 2. J Neurol Sci 378:187–192. https://doi.org/10.1016/j.jns.2017.05.013</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2017.05.013</ArticleId>
            <ArticleId IdType="pubmed">28566162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Weijs R, Okkersen K, van Engelen B et al (2021) Human brain pathology in myotonic dystrophy type 1: A systematic review. Neuropathology 41(1):3–20. https://doi.org/10.1111/neup.12721</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/neup.12721</ArticleId>
            <ArticleId IdType="pubmed">33599033</ArticleId>
            <ArticleId IdType="pmc">7986875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pascual-Gilabert M, López-Castel A, Artero R (2021) Myotonic dystrophy type 1 drug development: A pipeline toward the market. Drug Discov Today 26(7):1765–1772. https://doi.org/10.1016/j.drudis.2021.03.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.drudis.2021.03.024</ArticleId>
            <ArticleId IdType="pubmed">33798646</ArticleId>
            <ArticleId IdType="pmc">8372527</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H (2019) Neurofilament light chain as a biomarker in neurological disorders. J Neurol Neurosurg Psychiatry 90(8):870–881. https://doi.org/10.1136/jnnp-2018-320106</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2018-320106</ArticleId>
            <ArticleId IdType="pubmed">30967444</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teunissen CE, Petzold A, Bennett JL et al (2009) A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 73(22):1914–1922. https://doi.org/10.1212/WNL.0b013e3181c47cc2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3181c47cc2</ArticleId>
            <ArticleId IdType="pubmed">19949037</ArticleId>
            <ArticleId IdType="pmc">2839806</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. https://doi.org/10.1016/0022-3956(75)90026-6</Citation>
        </Reference>
        <Reference>
          <Citation>Carlesimo GA, Caltagirone C, Gainotti G. The mental deterioration battery: normative data, diagnostic reliability and qualitative analyses of cognitive impairment. The group for the standardization of the mental deterioration battery. Eur Neurol. 1996;36(6):378–384. https://doi.org/10.1159/000117297</Citation>
        </Reference>
        <Reference>
          <Citation>Caffarra P, Vezzadini G, Dieci F, Zonato F, Venneri A (2002) Rey-Osterrieth complex figure: normative values in an Italian population sample. Neurol Sci 22(6):443–447. https://doi.org/10.1007/s100720200003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s100720200003</ArticleId>
            <ArticleId IdType="pubmed">11976975</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gainotti G, Marra C, Villa G (2001) A double dissociation between accuracy and time of execution on attentional tasks in Alzheimer’s disease and multi-infarct dementia. Brain 124(Pt 4):731–738. https://doi.org/10.1093/brain/124.4.731</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/124.4.731</ArticleId>
            <ArticleId IdType="pubmed">11287373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marra C, Gainotti G, Scaricamazza E, Piccininni C, Ferraccioli M, Quaranta D. The multiple features target cancellation (MFTC): an attentional visual conjunction search test. Normative values for the Italian population. Neurol Sci. 2013;34(2):173–180. https://doi.org/10.1007/s10072-012-0975-3 .</Citation>
        </Reference>
        <Reference>
          <Citation>Quaranta D, Caprara A, Piccininni C, Vita MG, Gainotti G, Marra C (2016) Standardization, clinical validation, and typicality norms of a new test assessing semantic verbal fluency. Arch Clin Neuropsychol 31(5):434–445. https://doi.org/10.1093/arclin/acw034</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/arclin/acw034</ArticleId>
            <ArticleId IdType="pubmed">27353431</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monaco M, Costa A, Caltagirone C, Carlesimo GA (2015) Erratum to: Forward and backward span for verbal and visuo-spatial data: standardization and normative data from an Italian adult population. Neurol Sci 36(2):345–347. https://doi.org/10.1007/s10072-014-2019-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10072-014-2019-7</ArticleId>
            <ArticleId IdType="pubmed">25491661</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. AJR Am J Roentgenol. 1987;149(2):351–356. https://doi.org/10.2214/ajr.149.2.351</Citation>
        </Reference>
        <Reference>
          <Citation>Mathieu J, Boivin H, Meunier D, Gaudreault M, Bégin P (2001) Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology 56(3):336–340. https://doi.org/10.1212/wnl.56.3.336</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/wnl.56.3.336</ArticleId>
            <ArticleId IdType="pubmed">11171898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valentino P, Marnetto F, Martire S et al (2021) Serum neurofilament light chain levels in healthy individuals: A proposal of cut-off values for use in multiple sclerosis clinical practice. Mult Scler Relat Disord 54:103090. https://doi.org/10.1016/j.msard.2021.103090</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.msard.2021.103090</ArticleId>
            <ArticleId IdType="pubmed">34182224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meola G, Sansone V (2007) Cerebral involvement in myotonic dystrophies. Muscle Nerve 36(3):294–306. https://doi.org/10.1002/mus.20800</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.20800</ArticleId>
            <ArticleId IdType="pubmed">17486579</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gagnon C, Chouinard MC, Laberge L et al (2010) Health supervision and anticipatory guidance in adult myotonic dystrophy type 1. Neuromuscul Disord 20(12):847–851. https://doi.org/10.1016/j.nmd.2010.08.006</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nmd.2010.08.006</ArticleId>
            <ArticleId IdType="pubmed">20884209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thornton CA. Myotonic dystrophy. Neurol Clin. 2014;32(3):705-viii. https://doi.org/10.1016/j.ncl.2014.04.011</Citation>
        </Reference>
        <Reference>
          <Citation>Hamilton MJ, McLean J, Cumming S et al (2018) Outcome measures for central nervous system evaluation in myotonic dystrophy type 1 may be confounded by deficits in motor function or insight. Front Neurol 9:780. https://doi.org/10.3389/fneur.2018.00780</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.00780</ArticleId>
            <ArticleId IdType="pubmed">30333784</ArticleId>
            <ArticleId IdType="pmc">6176265</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Minnerop M, Gliem C, Kornblum C (2018) Current progress in CNS imaging of myotonic dystrophy. Front Neurol 9:646. https://doi.org/10.3389/fneur.2018.00646</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2018.00646</ArticleId>
            <ArticleId IdType="pubmed">30186217</ArticleId>
            <ArticleId IdType="pmc">6110944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gliem C, Minnerop M, Roeske S et al (2019) Tracking the brain in myotonic dystrophies: A 5-year longitudinal follow-up study. PLoS ONE 14(3):e0213381. https://doi.org/10.1371/journal.pone.0213381</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0213381</ArticleId>
            <ArticleId IdType="pubmed">30845252</ArticleId>
            <ArticleId IdType="pmc">6405094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labayru G, Jimenez-Marin A, Fernández E et al (2020) Neurodegeneration trajectory in pediatric and adult/late DM1: A follow-up MRI study across a decade. Ann Clin Transl Neurol 7(10):1802–1815. https://doi.org/10.1002/acn3.51163</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/acn3.51163</ArticleId>
            <ArticleId IdType="pubmed">32881379</ArticleId>
            <ArticleId IdType="pmc">7545612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hendricks R, Baker D, Brumm J, Davancaze T, Harp C, Herman A, Büdingen HV, Townsend M, Fischer SK (2019) Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood. Bioanalysis 11(15):1405–1418. https://doi.org/10.4155/bio-2019-0163</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4155/bio-2019-0163</ArticleId>
            <ArticleId IdType="pubmed">31401845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Disanto G, Barro C, Benkert P et al (2017) Serum neurofilament light: A biomarker of neuronal damage in multiple sclerosis. Ann Neurol 81(6):857–870. https://doi.org/10.1002/ana.24954</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.24954</ArticleId>
            <ArticleId IdType="pubmed">28512753</ArticleId>
            <ArticleId IdType="pmc">5519945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khalil M, Pirpamer L, Hofer E et al (2020) Serum neurofilament light levels in normal aging and their association with morphologic brain changes. Nat Commun 11(1):812. https://doi.org/10.1038/s41467-020-14612-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-14612-6</ArticleId>
            <ArticleId IdType="pubmed">32041951</ArticleId>
            <ArticleId IdType="pmc">7010701</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saak A, Benkert P, Akgün K et al (2021) Serum neurofilament light chain: a marker of nervous system damage in myopathies. Front Neurosci 15:791670. https://doi.org/10.3389/fnins.2021.791670</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fnins.2021.791670</ArticleId>
            <ArticleId IdType="pubmed">34975387</ArticleId>
            <ArticleId IdType="pmc">8718922</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laforce RJ, Dallaire-Théroux C, Racine AM, et al. Tau positron emission tomography, cerebrospinal fluid and plasma biomarkers of neurodegeneration, and neurocognitive testing: an exploratory study of participants with myotonic dystrophy type 1 [published online ahead of print, 2022 Feb 1]. J Neurol. 2022 https://doi.org/10.1007/s00415-022-10970-x</Citation>
        </Reference>
        <Reference>
          <Citation>van der Plas E, Long JD, Koscik TR et al (2022) Blood-based markers of neuronal injury in adult-onset myotonic dystrophy type 1. Front Neurol 12:791065. https://doi.org/10.3389/fneur.2021.791065</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2021.791065</ArticleId>
            <ArticleId IdType="pubmed">35126292</ArticleId>
            <ArticleId IdType="pmc">8810511</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otero BA, Poukalov K, Hildebrandt RP et al (2021) Transcriptome alterations in myotonic dystrophy frontal cortex. Cell Rep 34(3):108634. https://doi.org/10.1016/j.celrep.2020.108634</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2020.108634</ArticleId>
            <ArticleId IdType="pubmed">33472074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kerner NA, Roose SP (2016) Obstructive Sleep Apnea is Linked to Depression and Cognitive Impairment: Evidence and Potential Mechanisms. Am J Geriatr Psychiatry 24(6):496–508. https://doi.org/10.1016/j.jagp.2016.01.134</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jagp.2016.01.134</ArticleId>
            <ArticleId IdType="pubmed">27139243</ArticleId>
            <ArticleId IdType="pmc">5381386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Modoni A, Silvestri G, Pomponi MG et al (2004) Characterization of the pattern of cognitive impairment in myotonic dystrophy type 1. Arch Neurol 61(12):1943–1947. https://doi.org/10.1001/archneur.61.12.1943</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.61.12.1943</ArticleId>
            <ArticleId IdType="pubmed">15596617</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuan A, Sershen H, Veeranna, et al. Neurofilament subunits are integral components of synapses and modulate neurotransmission and behavior in vivo. Mol Psychiatry. 2015;20(8):986–994. https://doi.org/10.1038/mp.2015.45</Citation>
        </Reference>
        <Reference>
          <Citation>Bavato F, Cathomas F, Klaus F et al (2021) Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. J Psychiatr Res 140:141–148. https://doi.org/10.1016/j.jpsychires.2021.05.072</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpsychires.2021.05.072</ArticleId>
            <ArticleId IdType="pubmed">34116440</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Conio B, Martino M, Magioncalda P et al (2020) Opposite effects of dopamine and serotonin on resting-state networks: review and implications for psychiatric disorders. Mol Psychiatry 25(1):82–93. https://doi.org/10.1038/s41380-019-0406-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41380-019-0406-4</ArticleId>
            <ArticleId IdType="pubmed">30953003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra L, Silvestri G, Petrucci A et al (2014) Abnormal functional brain connectivity and personality traits in myotonic dystrophy type 1. JAMA Neurol 71(5):603–611. https://doi.org/10.1001/jamaneurol.2014.130</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2014.130</ArticleId>
            <ArticleId IdType="pubmed">24664202</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra L, Mancini M, Silvestri G et al (2016) Brain connectomics’ modification to clarify motor and nonmotor features of myotonic dystrophy type 1. Neural Plast 2016:2696085. https://doi.org/10.1155/2016/2696085</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1155/2016/2696085</ArticleId>
            <ArticleId IdType="pubmed">27313901</ArticleId>
            <ArticleId IdType="pmc">4897716</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sugiyama A, Sone D, Sato N et al (2017) Brain gray matter structural network in myotonic dystrophy type 1. PLoS ONE 12(11):e0187343. https://doi.org/10.1371/journal.pone.0187343</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0187343</ArticleId>
            <ArticleId IdType="pubmed">29095898</ArticleId>
            <ArticleId IdType="pmc">5667809</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Serra L, Bianchi G, Bruschini M et al (2020) Abnormal cortical thickness is associated with deficits in social cognition in patients with myotonic dystrophy type 1. Front Neurol 11:113. https://doi.org/10.3389/fneur.2020.00113</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fneur.2020.00113</ArticleId>
            <ArticleId IdType="pubmed">32180756</ArticleId>
            <ArticleId IdType="pmc">7059122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Labayru G, Diez I, Sepulcre J et al (2019) Regional brain atrophy in gray and white matter is associated with cognitive impairment in Myotonic Dystrophy type 1. Neuroimage Clin 24:102078. https://doi.org/10.1016/j.nicl.2019.102078</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nicl.2019.102078</ArticleId>
            <ArticleId IdType="pubmed">31795042</ArticleId>
            <ArticleId IdType="pmc">6861566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antonini G, Mainero C, Romano A et al (2004) Cerebral atrophy in myotonic dystrophy: a voxel based morphometric study. J Neurol Neurosurg Psychiatry 75(11):1611–1613. https://doi.org/10.1136/jnnp.2003.032417</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.2003.032417</ArticleId>
            <ArticleId IdType="pubmed">15489397</ArticleId>
            <ArticleId IdType="pmc">1738796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romeo V, Pegoraro E, Ferrati C et al (2010) Brain involvement in myotonic dystrophies: neuroimaging and neuropsychological comparative study in DM1 and DM2. J Neurol 257(8):1246–1255. https://doi.org/10.1007/s00415-010-5498-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-010-5498-3</ArticleId>
            <ArticleId IdType="pubmed">20221771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wozniak JR, Mueller BA, Lim KO, Hemmy LS, Day JW (2014) Tractography reveals diffuse white matter abnormalities in Myotonic Dystrophy Type 1. J Neurol Sci 341(1–2):73–78. https://doi.org/10.1016/j.jns.2014.04.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jns.2014.04.005</ArticleId>
            <ArticleId IdType="pubmed">24768314</ArticleId>
            <ArticleId IdType="pmc">4042407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernández-Hernández O, Guiraud-Dogan C, Sicot G et al (2013) Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behavior. Brain 136(Pt 3):957–970. https://doi.org/10.1093/brain/aws367</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/aws367</ArticleId>
            <ArticleId IdType="pubmed">23404338</ArticleId>
            <ArticleId IdType="pmc">3580270</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
